selected publications
-
academic article
- Tögel LNightingale RWu RChüeh ACAl-Obaidi SLuk IDávalos-Salas MChionh FMurone CBuchanan DDChatterton ZSieber OMArango DTebbutt NCWilliams DDhillon ASMariadason JM. DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Scientific Reports. 8. 2018
- Luk IYReehorst CMMariadason JM. ELF3, ELF5, EHF and SPDEF transcription factors in tissue homeostasis and cancer. Molecules. 23. 2018
- Eissmann MFDijkstra CWouters MABaloyan DMouradov DNguyen PMDavalos-Salas MPutoczki TLSieber OMMariadason JMErnst MMasson F. Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner. Cancer immunology research. 6:409-421. 2018
- Lau DKTay RYYeung YHChionh FMooi JMurone CSkrinos EPrice TJMariadason JMTebbutt NC. Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. British Journal of Cancer. 118:966-971. 2018
- Dopeso HRodrigues PBilic JBazzocco SCarton-Garcia FMacaya IGuimaraes de Marcondes PAnguita EMasanas MJimenez-Flores LMMartinez-Barriocanal ANieto RSegura MFSchwartz SMariadason JMArango D. Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer. British Journal of Cancer. 118:106-116. 2018
- Mooi JKWirapati PAsher RLee CKSavas PSPrice TJTownsend AHardingham JBuchanan DWilliams DTejpar SMariadason JMTebbutt NC. The prognostic impact of Consensus Molecular Subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.. Annals of Oncology. 2018
- Chüeh ACTse JWTDickinson MIoannidis PJenkins LTogel LTan BLuk IDavalos Salas MNightingale RThompson MRWilliams BRGLessene GLee EFFairlie WDDhillon ASMariadason JM. ATF3 Repression of BCL-X L Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types. Clinical Cancer Research. 23:5573-5584. 2017
- Tse JWTJenkins LChionh FMariadason J. Aberrant DNA methylation in colorectal cancer: What should we target?. Trends in Cancer. 3:698-712. 2017
- Wang JMouradov DWang XJorissen RNChambers MCZimmerman LJVasaikar SLove CGLi SLowes KLeuchowius K-JJousset HWeinstock JYau CMariadason JShi ZBan YChen XCoffey RJCSlebos RJCBurgess AWLiebler DCZhang BSieber OM. Colorectal cancer cell line proteomes are representative of primary tumors and predict drug sensitivity. Gastroenterology. 153:1082-1095. 2017
- Yeung YLau DKChionh FTran HTse JWTWeickhardt AJNikfarjam MScott AMTebbutt NCMariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. Molecular Oncology. 11:1130-1142. 2017
- Mateo-Lozano SBazzocco SRodrigues PMazzolini RAndretta EDopeso HFernández Ydel Llano EBilic JSuárez-López LMacaya ICartón-García FNieto RJimenez-Flores LMde Marcondes PGNuñez YAfonso ECacci KHernández-Losa JLandolfi SAbasolo IRamón y Cajal SMariadason JMSchwartz SMatsui TArango D. Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. Scientific Reports. 7:1-12. 2017
- Tutuka CAndrews MMariadason JIoannidis PHudson CCebon JBehren A. PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. Molecular Cancer. 16:1-5. 2017
- Chüeh ACLiew M-SRussell PAWalkiewicz MJayachandran AStarmans MHWBoutros PCWright GBarnett SAMariadason JMJohn T. Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. Oncotarget. 8:74036-74048. 2017
- Chisanga DKeerthikumar SPathan MAriyaratne DKalra HBoukouris SMathew NAAl Saffar HGangoda LAng C-SSieber OMMariadason JMDasgupta RChilamkurti NMathivanan S. Colorectal cancer atlas: an integrative resource for genomic and proteomic annotations from colorectal cancer cell lines and tissues. Nucleic Acids Research. 44:D969-D974. 2016
- Patnaik SGeorge SPPham ERoy SSingh KMariadason JMKhurana S. By moonlighting in the nucleus, Villin regulates epithelial plasticity. Molecular Biology of the Cell. 27:535-548. 2016
- Togel LNightingale RChueh ACJayachandran ATran HPhesse TWu RSieber OMArango DDhillon ASDawson MADiez-Dacal BGahman TCFilippakopoulos PShiau AKMariadason JM. Dual targeting of bromodomain and extraterminal domain proteins, and WNT or MAPK signaling, Inhibits c-MYC expression and proliferation of colorectal cancer cells. Molecular Cancer Therapeutics. 15:1217-1226. 2016
- Pathan MKeerthikumar SAng C-SGangoda LQuek CYJWilliamson NAMouradov DSieber OMSimpson RJSalim ABacic AHill AFStroud DARyan MTAgbinya JIMariadason JMBurgess AWMathivanan S. FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics. 15:2597-2601. 2015
- Bazzocco SDopeso HCarton-Garcia FMacaya IAndretta EChionh FRodrigues PGarrido MAlazzouzi HNieto RSanchez ASchwartz SBilic JMariadason JMArango D. Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment. Clinical Cancer Research. 21:3695-3704. 2015
- Pereira LMariadason JMHannan RDDhillon AS. Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer. Frontiers in Oncology. 5. 2015
- Chueh ACTse JWTTögel LMariadason JM. Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells. Antioxidants and Redox Signaling. 23:66-84. 2015
- Gilan ODiesch JAmalia MJastrzebski KChueh ACVerrills NMPearson RBMariadason JMTulchinsky EHannan RDDhillon AS. PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity. Oncogene. 34:1333-1339. 2015
- Augustine TABaig MSood ABudagov TAtzmon GMariadason JMAparo SMaitra RGoel S. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. British Journal of Cancer. 112:313-318. 2015
- Weickhardt AJWilliams DSLee CKChionh FSimes JMurone CWilson KParry MMAsadi KScott AMPunt CJANagtegaal IDPrice TJMariadason JMTebbutt NC. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. British Journal of Cancer. 113:37-45. 2015
- Rodrigues PMacaya IBazzocco SMazzolini RAndretta EDopeso HMateo-Lozano SBilić JCartón-García FNieto RSuárez-López LAfonso ELandolfi SHernandez-Losa JKobayashi KCajal SRYTabernero JTebbutt NCMariadason JMSchwartz SArango D. RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. Nature Communications. 5:5458. 2014
- Shin JCarr ACorner GATögel LDávaos-Salas MTran HChueh ACAl-Obaidi SChionh FAhmed NBuchanan DDYoung JPMalo MSHodin RAArango DSieber OMAugenlicht LHDhillon ASWeber TKMariadason JM. The Intestinal Epithelial Cell Differentiation Marker Intestinal Alkaline Phosphatase (ALPi) Is Selectively Induced by Histone Deacetylase Inhibitors (HDACi) in Colon Cancer Cells in a Kruppel-like Factor 5 (KLF5)-dependent Manner. Journal of Biological Chemistry. 289:25306-25316. 2014
- Maitra RSeetharam RTesfa LAugustine TAKlampfer LCoffey MCMariadason JMGoel S. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. Oncotarget. 5:2807-2819. 2014
- Tan BSAnaka MRDeb SFreyer CEbert LMChueh ACAl-Obaidi SBehren AJayachandran ACebon JChen WMariadason JM. FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.. Oncotarget. 5:264-276. 2014
- Ung NPutoczki TLStylli SSNg IMariadason JMChan TAZhu HJLuwor RB. Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biology and Therapy. 15:623-632. 2014
- Mouradov DSloggett CJorissen RNLove CGLi SBurgess AWArango DStrausberg RLBuchanan DWormald SO'Connor LWilding JLBicknell DTomlinson IPMBodmer WFMariadason JMSieber OM. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Research. 74:3238-3247. 2014
- Aisner DLNguyen TTPaskulin DDLe ATHaney JSchulte NChionh FHardingham JMariadason JTebbutt NDoebele RCWeickhardt AJVarella-Garcia M. ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers . Molecular Cancer Research. 12:111-118. 2014
- Diesch JSanij EGilan OLove CTran HFleming NIEllul JAmalia MHaviv IPearson RBTulchinsky EMariadason JMSieber OMHannan RDDhillon AS. Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells. PLoS ONE. 9. 2014
- Lee STJi HGreening DWSpeirs RWHRigopoulos APillay VMurone CVitali AStühler KJohns TGCorner GAMariadason JMSimpson RJScott AM. Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts. Growth Factors. 31:154-164. 2013
- Andrews MCBehren AChionh FMariadason JVella LJDo HDobrovic ATebbutt NCebon J. BRAF inhibitor-driven tumor proliferation in akras-mutated colon carcinoma is not overcome by mek1/2 inhibition. Journal of Clinical Oncology. 31:e448-e451. 2013
- Mazzolini RRodrigues PBazzocco SDopeso HFerreira AMMateo-Lozano SAndretta EWoerner SMAlazzouzi HLandolfi SHernandez-Losa JMacAya ISuzuki HRamõn Y Cajal SMooseker MSMariadason JMGebert JHofstra RMWReventõs JYamamoto HSchwartz SArango D. Brush border myosin Ia inactivation in gastric but not endometrial tumors. International Journal of Cancer. 132:1790-1799. 2013
- Burvenich IJGLee FTCartwright GAO'Keefe GJMakris DCao DGong SChueh ACMariadason JMBrechbiel MWBeckman RAFujiwara KVon Roemeling RScott AM. Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008. Clinical Cancer Research. 19:5984-5993. 2013
- Mao MTian FMariadason JMTsao CCLemos RDayyani FVashisht Gopal YNJiang ZQWistuba IITang XMBornman WGBollag GMills GBPowis GDesai JGallick GEDavies MAKopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clinical Cancer Research. 19:657-667. 2013
- Fleming NIJorissen RNMouradov DChristie MSakthianandeswaren APalmieri MDay FLi STsui CLipton LDesai JJones ITMcLaughlin SWard RLHawkins NJRuszkiewicz ARMoore JZhu HJMariadason JMBurgess AWBusam DZhao QStrausberg RLGibbs PSieber OM. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Research. 73:725-735. 2013
- Pakay JLDiesch JGilan OYip Y-YSayan EKolch WMariadason JMHannan RDTulchinsky EDhillon AS. A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells. Oncogene. 31:1817-1824. 2012
- Mazzolini RDopeso HMateo-Lozano SChang WRodrigues PBazzocco SAlazzouzi HLandolfi SHernández-Losa JAndretta EAlhopuro PEspín EArmengol MTabernero JRamón Y Cajal SKloor MGebert JMariadason JMSchwartz SAaltonen LAMooseker MSArango D. Brush border Myosin Ia has tumor suppressor activity in the intestine. Proceedings of the National Academy of Sciences of USA. 109:1530-1535. 2012
- Weickhardt AJPrice TJChong GGebski VPavlakis NJohns TGAzad ASkrinos EFluck KDobrovic ASalemi RScott AMMariadason JMTebbutt NC. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology. 30:1505-1512. 2012
- Tan BBehren AAnaka MVella LCebon JMariadason JMChen W. FOXP3 is not mutated in human melanoma. Pigment Cell and Melanoma Research. 25:398-400. 2012
- Sood AMcClain DMaitra RBasu-Mallick ASeetharam RKaubisch ARajdev LMariadason JMTanaka KGoel S. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clinical Colorectal Cancer. 11:143-150. 2012
- Haigentz MKim MSarta CLin JKeresztes RSCulliney BGaba AGSmith RVShapiro GIChirieac LRMariadason JMBelbin TJGreally JMWright JJHaddad RI. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncology. 48:1281-1288. 2012
- Dhomen NSMariadason JTebbutt NScott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Critical Reviews in Oncogenesis. 17:31-50. 2012
- Arango DAl-Obaidi SWilliams DSDopeso HMazzolini RCorner GByun D-SCarr AAMurone CToegel LZeps NAaltonen LAIacopetta BMariadason JM. Villin expression Is frequently lost in poorly differentiated colon cancer. American Journal of Pathology. 180:1509-1521. 2012
- Smartt HJMGreenhough AOrdóñez-Morán PAl-Kharusi MCollard TJMariadason JMHuelsken JWilliams ACParaskeva C. β-catenin negatively regulates expression of the prostaglandin transporter PGT in the normal intestinal epithelium and colorectal tumour cells: A role in the chemopreventive efficacy of aspirin. British Journal of Cancer. 107:1514-1517. 2012
- Smartt HJMGreenhough AOrdóñez-Morán PTalero ECherry CAWallam CAParry LAl Kharusi MRoberts HRMariadason JMClarke ARHuelsken JWilliams ACParaskeva C. β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells. Gut. 61:1306-1314. 2012
- Byun D-SAhmed NNasser SShin JAl-Obaidi SGoel SCorner GAWilson AJFlanagan DJWilliams DSAugenlicht LHVincan EMariadason JM. Intestinal epithelial-specific PTEN inactivation results in tumor formation. American Journal of Physiology: Gastrointestinal and Liver Physiology. 301:G856-G864. 2011
- Wang DPeregrina KDhima ELin EYMariadason JMAugenlicht LH. Paneth cell marker expression in intestinal villi and colon crypts characterizes dietary induced risk for mouse sporadic intestinal cancer. Proceedings of the National Academy of Sciences of USA. 108:10272-10277. 2011
- Weickhardt AMariadason JTebbutt NJ. Weickhardt AC. Tebbutt NM. Mariadason J. Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway. Current Cancer Drug Targets. 10:824-833. 2010
- Gollamudi RGhalib MHDesai KKChaudhary IWong BEinstein MCoffey MGill GMMettinger KMariadason JMMani SGoel S. Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors. Investigational New Drugs. 28:641-649. 2010
- Patel VNBebek GMariadason JMWang DAugenlicht LHChance MR. Prediction and Testing of Biological Networks Underlying Intestinal Cancer. PLoS ONE. 5:e12497-e12497. 2010
- Janakiraman MVakiani EZeng ZPratilas CATaylor BSChitale DHalilovic EWilson MHuberman KRicarte Filho JCPersaud YLevine DAFagin JAJhanwar SCMariadason JMLash ALadanyi MSaltz LBHeguy APaty PBSolit DB. Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. Cancer Research. 70:5901-5911. 2010
- Wang DPezo RCCorner GSison CLesser MLShenoy SMMariadason JMSinger RHAugenlicht LH. Altered Dynamics of Intestinal Cell Maturation in Apc1638N/+ Mice. Cancer Research. 70:5348-5357. 2010
- Seetharam RNSood ABasu-Mallick AAugenlicht LHMariadason JMGoel S. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. Anticancer Research: international journal of cancer research and treatment. 30:2531-2538. 2010
- Dopeso HMateo-Lozano SElez ELandolfi SRamos Pascual FJHernandez-Losa JMazzolini RRodrigues PBazzocco SCarreras MJEspin EArmengol MWilson AJMariadason JMRamon y Cajal STabernero JSchwartz SArango D. Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment. Clinical Cancer Research. 16:2375-2382. 2010
- Yuan ZShin JWilson AGoel SLing YHAhmed NDopeso HJhawer MNasser SMontagna CFordyce KAugenlicht LHAaltonen LAArango DWeber TKMariadason JM. Correction: An A13 Repeat within the 3'-Untranslated Region of Epidermal Growth Factor Receptor (EGFR) Is Frequently Mutated in Microsatellite Instability Colon Cancers and Is Associated with Increased EGFR Expression. Cancer Research. 70:1275-1275. 2010
- Guilmeau SFlandez MMariadason JMAugenlicht LH. Heterogeneity of Jagged1 expression in human and mouse intestinal tumors: implications for targeting Notch signaling. Oncogene. 29:992-1002. 2010
- Wilson AJChueh ACTogel LCorner GAAhmed NGoel SByun D-SNasser SHouston MAJhawer MSmartt HJMMurray LBNicholas CHeerdt BGArango DAugenlicht LHMariadason JM. Apoptotic Sensitivity of Colon Cancer Cells to Histone Deacetylase Inhibitors Is Mediated by an Sp1/Sp3-Activated Transcriptional Program Involving Immediate-Early Gene Induction. Cancer Research. 70:609-620. 2010
- Ganepola GAPMazziotta RMWeeresinghe DCorner GAParish CJChang DHTebbutt NCMurone CAhmed NAugenlicht LHMariadason JM. Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors. Clinical and Experimental Metastasis. 27:1-9. 2010
- Yuan ZShin JWilson AGoel SLing Y-HAhmed NDopeso HJhawer MNasser SMontagna CFordyce KAugenlicht LHAaltonen LAArango DWeber TKMariadason JM. An A13 Repeat within the 3'-Untranslated Region of Epidermal Growth Factor Receptor (EGFR) Is Frequently Mutated in Microsatellite Instability Colon Cancers and Is Associated with Increased EGFR Expression. Cancer Research. 69:7811-7818. 2009
- Dopeso HMateo-Lozano SMazzolini RRodrigues PLagares-Tena LCeron JRomero JEsteves MLandolfi SHernandez-Losa JCastano JWilson AJRamon y Cajal SMariadason JMSchwartz SArango D. The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal Tumorigenesis. Cancer Research. 69:7430-7438. 2009
- Chang JChance MRNicholas CAhmed NGuilmeau SFlandez MWang DByun D-SNasser SAlbanese JMCorner GAHeerdt BGWilson AJAugenlicht LHMariadason JM. Proteomic changes during intestinal cell maturation in vivo. Journal of Proteomics. 71:530-546. 2008
- Li TYang WLi MByun D-STong CNasser SZhuang MArango DMariadason JMAugenlicht LH. Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Molecular Nutrition and Food Research. 52:1289-1299. 2008
- Mariadason JM. Making Sense of HDAC2 Mutations in Colon Cancer. Gastroenterology. 135:1457-1459. 2008
- Mariadason JM. Dissecting HDAC3-mediated tumor progression. Cancer Biology and Therapy. 7:1581-1583. 2008
- Wilson AJByun D-SNasser SMurray LBAyyanar KArango DFigueroa MMelnick AKao GDAugenlicht LHMariadason JM. HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21. Molecular Biology of the Cell. 19:4062-4075. 2008
- Jhawer MGoel SWilson AJMontagna CLing YHByun DSNasser SArango DShin JKlampfer LAugenlicht LHPerez-Soler RMariadason JM. Correction: Prediction of Response to Cetuximab. Cancer Research. 68:6859-6859. 2008
- Sohal DYeatts AYe KPellagatti AZhou LPahanish PMo YBhagat TMariadason JBoultwood JMelnick AGreally JVerma A. Meta-Analysis of Microarray Studies Reveals a Novel Hematopoietic Progenitor Cell Signature and Demonstrates Feasibility of Inter-Platform Data Integration. PLoS ONE. 3:e2965-e2965. 2008
- Mercier IVuolo MJasmin J-FMedina CMWilliams MMariadason JMQian HXue XPestell RGLisanti MPKitsis RN. ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle. 7:1640-1647. 2008
- Jhawer MGoel SWilson AJMontagna CLing Y-HByun D-SNasser SArango DShin JKlampfer LAugenlicht LHSoler RPMariadason JM. PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab. Cancer Research. 68:1953-1961. 2008
- Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics. 3:28-37. 2008
- Gassler NRoth WFunke BSchneider AHerzog FTischendorf JJWGrund KPenzel RBravo IGMariadason JEhemann VSykora JHaas TLWalczak HGanten TZentgraf HErb PAlonso AAutschbach FSchirmacher PKnüchel RKopitz J. Regulation of Enterocyte Apoptosis by Acyl-CoA Synthetase 5 Splicing. Gastroenterology. 133:587-598. 2007
- Tong CYin ZSong ZDockendorff AHuang CMariadason JFlavell RADavis RJAugenlicht LHYang W. c-Jun NH2-Terminal Kinase 1 Plays a Critical Role in Intestinal Homeostasis and Tumor Suppression. American Journal of Pathology. 171:297-303. 2007
- Smartt HJMGuilmeau SNasser SVNicholas CBancroft LSimpson SAYeh NYang WMariadason JMKoff AAugenlicht LH. p27kip1 Regulates cdk2 Activity in the Proliferating Zone of the Mouse Intestinal Epithelium: Potential Role in Neoplasia. Gastroenterology. 133:232-243. 2007
- Khabele DSon D-SParl AKGoldberg GLAugenlicht LHMariadason JMMontgomery Rice V. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy. Cancer Biology and Therapy. 6:795-801. 2007
- Davalos VDopeso HCastaño JWilson AJVilardell FRomero-Gimenez JEspín EArmengol MCapella GMariadason JMAaltonen LASchwartz SArango D. EPHB4 and Survival of Colorectal Cancer Patients. Cancer Research. 66:8943-8948. 2006
- Wilson AJByun D-SPopova NMurray LBL'Italien KSowa YArango DVelcich AAugenlicht LHMariadason JM. Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer. Journal of Biological Chemistry. 281:13548-13558. 2006
- Paroder VSpencer SRParoder MArango DSchwartz SMariadason JMAugenlicht LHEskandari SCarrasco N. Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: Molecular characterization of SMCT. Proceedings of the National Academy of Sciences of USA. 103:7270-7275. 2006
- Prokhortchouk ASansom OSelfridge JCaballero IMSalozhin SAithozhina DCerchietti LMeng FGAugenlicht LHMariadason JMHendrich BMelnick AProkhortchouk EClarke ABird A. Kaiso-Deficient Mice Show Resistance to Intestinal Cancer. Molecular and Cellular Biology. 26:199-208. 2006
- Alazzouzi HDavalos VKokko ADomingo EWoerner SMWilson AJKonrad LLaiho PEspín EArmengol MImai KYamamoto HMariadason JMGebert JFAaltonen LASchwartz SArango D. Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors. Cancer Research. 65:10170-10173. 2005
- Mariadason JMNicholas CL’Italien KEZhuang MSmartt HJMHeerdt BGYang WCorner GAWilson AJKlampfer LArango DAugenlicht LH. Gene expression profiling of intestinal epithelial cell maturation along the crypt-villus axis. Gastroenterology. 128:1081-1088. 2005
- VELCICH ACORNER GPAUL DZHUANG MMARIADASON JLABOISSE CAUGENLICHT L. Quantitative rather than qualitative differences in gene expression predominate in intestinal cell maturation along distinct cell lineages. Experimental Cell Research. 304:28-39. 2005
- Arango DWilson AJShi QCorner GAArañes MJNicholas CLesser MMariadason JMAugenlicht LH. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. British Journal of Cancer. 91:1931-1946. 2004
- Mariadason JMArango DAugenlicht LH. Customizing chemotherapy for colon cancer: the potential of gene expression profiling. Drug Resistance Updates. 7:209-218. 2004
- Mariadason JMArango DShi QWilson AJCorner GANicholas CAranes MJLesser MSchwartz ELAugenlicht LH. Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin. Cancer Research. 63:8791-8812. 2003
- Klampfer LHuang JCorner GMariadason JArango DSasazuki TShirasawa SAugenlicht L. Oncogenic Ki-Ras Inhibits the Expression of Interferon-responsive Genes through Inhibition of STAT1 and STAT2 Expression. Journal of Biological Chemistry. 278:46278-46287. 2003
- Arango DMariadason JMWilson AJYang WCorner GANicholas CAranes MJAugenlicht LH. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. British Journal of Cancer. 89:1757-1765. 2003
- Wilson AJArango DMariadason JMHeerdt BGAugenlicht LH. TR3/Nur77 in colon cancer cell apoptosis. Cancer Research. 63:5401-5407. 2003
- Augenlicht LShi LMariadason JLaboisse CVelcich A. Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation. Oncogene. 22:4983-4992. 2003
- Mariadason JMAugenlicht LHArango D. Microarray analysis in the clinical management of cancer. Hematology / Oncology Clinics of North America. 17:377-387. 2003
- Mariadason JMArango DCorner GAArañes MJHotchkiss KAYang WAugenlicht LH. A gene expression profile that defines colon cell maturation in vitro. Cancer Research. 62:4791-4804. 2002
- Yang WCVelcich AMariadason JNicholas CCorner GHouston MAugenlicht LHEdelmann WAugenlicht LHKucherlapati RHolt PR. p21WAF1/cip1 is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Research. 61:6297-6302. 2001
- Mariadason JMBordonaro MAslam FShi LKuraguchi MVelcich AAugenlicht LH. Down-regulation of β-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Research. 61:3465-3471. 2001
- Mariadason JMVelcich AWilson AJAugenlicht LHGibson PR. Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology. 120:889-899. 2001
-
Heerdt BGHouston MAMariadason JMAugenlicht LH. Dissociation of staurosporine-induced apoptosis from G
2 -M arrest in SW620 human colonic carcinoma cells: Initiation of the apoptotic cascade is associated with elevation of the mitochondrial membrane potential (Δψ(m)). Cancer Research. 60:6704-6713. 2000 - Mariadason JMCorner GAAugenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: Comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Research. 60:4561-4572. 2000
- Mariadason JJohn M. MariadasonRickard KLBarkla DHAugenlicht LHPeter R. Gibson. Divergent phenotypic patterns and commitment to apoptosis of Caco-2 cells during spontaneous and butyrate-induced differentiation. Journal of Cellular Physiology. 183:347-354. 2000
- Rickard KLGibson PRWilson NJMariadason JMPhillips WA. Short-chain fatty acids reduce expression of specific protein kinase C isoforms in human colonic epithelial cells. Journal of Cellular Physiology. 182:222-231. 2000
- Bordonaro MMariadason JMAslam FHeerdt BGAugenlicht LH. Butyrate-induced apoptotic cascade in colonic carcinoma cells: Modulation of the β-catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin. Molecular Cancer Research. 10:713-720. 1999
- Mariadason JMKilias DCatto-Smith AGibson PR. Effect of butyrate on paracellular permeability in rat distal colonic mucosa ex vivo. Journal of Gastroenterology and Hepatology. 14:873-879. 1999
- Gibson PRNov RFielding MMcintyre AFinch CFRosella OMariadason JMBarkla DHYoung GP. Relationship of hydrolase activities to epithelial cell turnover in distal colonic mucosa of normal rats. Journal of Gastroenterology and Hepatology. 14:866-872. 1999
- Gibson PRRosella OWilson AJMariadason JMRickard KByron KBarkla DH. Colonic epithelial cell activation and the paradoxical effects of butyrate. Carcinogenesis. 20:539-544. 1999
- Mariadason JMCatto-Smith AGibson PR. Modulation of distal colonic epithelial barrier function by dietary fibre in normal rats. Gut. 44:394-399. 1999
- Mariadason JMBarkla DHGibson PR. Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. American Journal of Physiology: Gastrointestinal and Liver Physiology. 272:G705-G712. 1997
- Gibson PRAnderson RPMariadason JMWilson AJ. Protective role of the epithelium of the small intestine and colon. Inflammatory Bowel Diseases. 2:279-302. 1996
-
chapter
- Mooi JKLuk IYMariadason JM. Cell line models of molecular subtypes of colorectal cancer. Colorectal Cancer. 3-26. 2018
- Velcich AKlampfer LMariadason JSmartt HGuilmeau SMaier SYang WChristman JHeerdt BAugenlicht L. Genetics and Epigenetics in Cancer Biology. 25-56. 2006
-
comment
- Mariadason JMTebbutt NC. Biomarkers of 5-fu response in colon cancer [Brief Commentary]. Cancer Biology and Therapy. 771-772. 2011
-
conference paper
- Mooi JWirapati PAsher RLee CSavas PPrice TJTejpar SMariadason JTebbutt N. Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial. Annals of Oncology. 2017
- Weickhardt ALau DLavis AGarms MMariadason J. ACQUIRED RESISTANCE TO THE FIBROBLAST GROWTH FACTOR RECEPTOR ( FGFR) INHIBITOR BGJ398 IN FGFR3 DRIVEN BLADDER CANCER IS OVERCOME BY CO-TARGETING THE RAPIDLY INDUCED PAXL OR PERBB3 PATHWAYS. Asia Pacific Journal of Clinical Oncology. 63-63. 2017
- Chionh FJMGebski VChueh ACAl-Obaidi SJWelckhardt AJLee CWilliams DSMurone CWilson KScott AMSimes JPrice TJMariadason JMTebbutt NC. Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX Inter study.. Journal of Clinical Oncology. 2014
- Weickhardt AJWilliams DLee CSimes JMurone CWilson KCummins MAsadi KPrice TJMariadason JTebbutt NC. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.. Journal of Clinical Oncology. 2011
- Augenlicht LHYang WMariadason JVelcich AKlampfer LLipkin MYang K. Interaction of Genetic and Dietary Factors in Mouse Intestinal Tumorigenesis. The Journal of Nutrition. 2695S-2696S. 2006
- Yang KYang WMariadason JVelcich ALipkin MAugenlicht L. Dietary Components Modify Gene Expression: Implications for Carcinogenesis. The Journal of Nutrition. 2710-2714. 2005
- Augenlicht LHVelcich AKlampfer LHuang JCorner GAranes MLaboisse CRigas BLipkin MYang KShi QLesser MHeerdt BArango DYang WWilson AMariadason JM. Application of Gene Expression Profiling to Colon Cell Maturation, Transformation and Chemoprevention. The Journal of Nutrition. 2410S-2416S. 2003
- Augenlicht LHMariadason JMWilson AArango DYang WHeerdt BGVelcich A. Short Chain Fatty Acids and Colon Cancer. The Journal of Nutrition. 3804S-3808S. 2002
- Augenlicht LHHeerdt BGMariadason JMYang WCWilson AJFragale AVelcich A. Environment-gene interactions in intestinal cancer. European Journal of Cancer Prevention. S12-S17. 2002
- Augenlicht LVelcich AMariadason JBordonaro MHeerdt B. Colonic cell proliferation, differentiation, and apoptosis. Advances in Experimental Medicine and Biology. 15-22. 2000
- AUGENLICHT LHBORDONARO MHEERDT BGMARIADASON JVELCICH A. Cellular Mechanisms of Risk and Transformation. Annals of the New York Academy of Sciences. 20-31. 1999
-
erratum
- Shin JCarr ACorner GATögel LDávalos-Salas MTran HChueh ACAl-Obaidi SChionh FAhmed NBuchanan DDYoung JPMalo MSHodin RAArango DSieber OMAugenlicht LHDhillon ASWeber TKMariadason JM. Correction: The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner (Journal of Biological Chemistry). Journal of Biological Chemistry. 15392-15392. 2015
-
abstract
- Hodgson-Garms MMariadason JWeickhardt A. Mechanisms of acquired resistance to the fibroblast growth factor receptor (FGFR) inhibitor BGJ398 in FGFR driven bladder cancer. Annals of Oncology. 2016